Search Results - jason+mclellan

9 Results

Sort By:

One and done: A variant-proof coronavirus vaccine

Background/problem Coronaviruses, including SARS-CoV-2, caused the COVID-19 pandemic of plague-like infectiousness with >770 M cases and 6.9M deaths worldwide. Vaccination provided protection against severe disease progression, hospitalization, and mortality. However, current vaccine technology is in an arms race against the continual evolution...

Published: 6/21/2024 | Inventor(s): Jason McLellan, Ling Zhou, Ching-Lin Hsieh, Rommie Amaro, Masaru Kanekiyo, Sila Ataca, Yaroslav Tsybovsky, Xandra Nuqui, Lorenzo Casalino, Mohamed Shehata

Keywords(s):

Category(s): Life sciences > Therapeutics, Life sciences > Therapeutics > Vaccines

Prefusion Coronavirus Spike Proteins and Their Use

Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Michael Joyce, Kizzmekia Corbett, Hadi Yassine, Jason McLellan, Christopher Cottrell, Nianshuang Wang, Jesper Pallesen, Hannah Turner, Robert Kirchdoerfer, Andrew Ward, Barney Graham

Keywords(s): CORONAVIRUS, DC5BXX, proteins, Stabilized, VACCINATION

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines

Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine

The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization...

Published: 7/25/2024 | Inventor(s): Jason Gorman, Gilad Ofek, Marie Pancera, Mallika Sastry, Sanjay Srivatsan, Yongping Yang, Lei Chen, Cinque Soto, Tongqing Zhou, Barney Graham, Peter Kwong, Masaru Kanekiyo, Michael Joyce, Baoshan Zhang, Guillaume Stewart-Jones, Jeffrey Boyington, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason McLellan

Keywords(s): CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Intraocular Optic Capture Device (IOCD)

Competitive Advantages Made of FDA approved material Minimal incision required Compatible with single-piece IOL’s including premium lenses Allows re-fixation of dislocated toric IOL’s Summary A device called Intraocular Optic Capture Device (IOCD) was developed by USF researchers for IOL re-fixation. The first of its kind, this...

Published: 7/18/2023 | Inventor(s): Jason So

Keywords(s): Health Tech, Medical Devices, Optics and Imaging

Category(s): Technology Classifications > Medical > Ophthalmology, Technology Classifications > Medical > Medical Devices, Technology Classifications > Medical

Immunotherapy That Converts Glioblastoma Cells Into Immune Cells to Attack Cancerous Tumors

Converts Cancer Cells to Immune Cells that Recruit Body’s Own Immune System to Target Brain Tumors This immunotherapy directly reprograms cancer cells into immune cells, specifically dendritic cells, making the reprogrammed cancer cells a therapy for the rest of the tumor. Glioblastoma (GBM) is the most common and lethal brain cancer in adults....